Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?
OBJECTIVES: To compare the cost-effectiveness of therapy of gastroesophageal reflux disease with esomeprazole and other proton pump inhibitors (PPIs) in Poland.
MATERIALS & METHODS: Studies comparing esomeprazole with other PPIs in the treatment of erosive esophagitis, non-erosive reflux disease and gastroesophageal reflux disease maintenance therapy were systematically reviewed. 9 randomized clinical trials were selected, meta-analyses were conducted. Cost data derived from Polish Ministry of Health and Pharmacies in Wroclaw.
RESULTS: In the treatment of erosive esophagitis esomeprazole was significantly more effective than other PPIs. Both for 4- and 8-week therapy respective incremental cost-effectiveness ratio values were acceptably low. Differences in effectiveness of non-erosive reflux disease therapy were not significant. The replacement of pantoprazole 20 mg with more effective esomeprazole 20 mg in the 6-month maintenance therapy was associated with a substantially high incremental cost-effectiveness ratio.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Journal of comparative effectiveness research - 5(2016), 2 vom: 15. März, Seite 169-78 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Petryszyn, Pawel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2-Pyridinylmethylsulfinylbenzimidazoles |
|---|
| Anmerkungen: |
Date Completed 11.01.2017 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/cer.15.63 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM258141867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM258141867 | ||
| 003 | DE-627 | ||
| 005 | 20231224184348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/cer.15.63 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0860.xml |
| 035 | |a (DE-627)NLM258141867 | ||
| 035 | |a (NLM)26946951 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petryszyn, Pawel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland? |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: To compare the cost-effectiveness of therapy of gastroesophageal reflux disease with esomeprazole and other proton pump inhibitors (PPIs) in Poland | ||
| 520 | |a MATERIALS & METHODS: Studies comparing esomeprazole with other PPIs in the treatment of erosive esophagitis, non-erosive reflux disease and gastroesophageal reflux disease maintenance therapy were systematically reviewed. 9 randomized clinical trials were selected, meta-analyses were conducted. Cost data derived from Polish Ministry of Health and Pharmacies in Wroclaw | ||
| 520 | |a RESULTS: In the treatment of erosive esophagitis esomeprazole was significantly more effective than other PPIs. Both for 4- and 8-week therapy respective incremental cost-effectiveness ratio values were acceptably low. Differences in effectiveness of non-erosive reflux disease therapy were not significant. The replacement of pantoprazole 20 mg with more effective esomeprazole 20 mg in the 6-month maintenance therapy was associated with a substantially high incremental cost-effectiveness ratio | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a cost effectiveness | |
| 650 | 4 | |a esomeprazole | |
| 650 | 4 | |a gastroesophageal reflux | |
| 650 | 7 | |a 2-Pyridinylmethylsulfinylbenzimidazoles |2 NLM | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 650 | 7 | |a Pantoprazole |2 NLM | |
| 650 | 7 | |a D8TST4O562 |2 NLM | |
| 650 | 7 | |a Esomeprazole |2 NLM | |
| 650 | 7 | |a N3PA6559FT |2 NLM | |
| 700 | 1 | |a Staniak, Aleksandra |e verfasserin |4 aut | |
| 700 | 1 | |a Grzegrzolka, Jedrzej |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of comparative effectiveness research |d 2012 |g 5(2016), 2 vom: 15. März, Seite 169-78 |w (DE-627)NLM218708033 |x 2042-6313 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2016 |g number:2 |g day:15 |g month:03 |g pages:169-78 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/cer.15.63 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2016 |e 2 |b 15 |c 03 |h 169-78 | ||